Cat. No. 1284
Chemical Name: 6-(Benzylamino)-2-(2-hydroxyethylam
Biological ActivityCyclin-dependent kinase inhibitor that competes for the ATP binding site of the kinase. Selectively inhibits cdc2/cyclin B (IC50 = 7 μM), cdk2/cyclin A (IC50 = 7 μM), cdk2/cyclin E (IC50 = 7 μM), cdk/p35 kinase (IC50 = 3 μM) and ERK1/MAP kinase (IC50 = 25 μM). Arrests human fibroblasts in the G1 phase.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Alessi et al (1998) The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp.Cell.Res. 245 8. PMID: 9828096.
Abraham et al (1995) Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol.Cell 83 105. PMID: 7549905.
Vesely et al (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur.J.Biochem. 224 771. PMID: 7925396.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Olomoucine include:
Cannon et al (2009) Association of luteinizing hormone receptor gene expression with cell cycle progression in granulosa cells. Am J Physiol Endocrinol Metab 296 E1392. PMID: 19293332.
Do you know of a great paper that uses Olomoucine from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Olomoucine, supplier, Cyclin-dependent, protein, kinases, inhibitors, inhibits, Cdks, Tocris Bioscience, Cyclin-Dependent Protein Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.